Aphaia Pharma Announces Enrollment of First Patient in Phase 2 Study of APH-012 for Chronic Weight Management in Individuals with Obesity

Source :: GlobeNewswire. October 27, 2022
Publication Year :: 2022
Abstract: ZUG, Switzerland, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage biopharmaceutical company harnessing precision-targeted drug delivery technology for the treatment and prevention of metabolic diseases, today announced that [...]

Subjects :: United States. Food and Drug Administration -- Technology application
Medical research -- Technology application
Medicine, Experimental -- Technology application
Obesity -- Care and treatment
Drugs -- Vehicles
Drug approval -- Technology application
Drug delivery systems -- Technology application
Technology application
Banking, finance and accounting industries
Business

Tools